Breaking News Instant updates and real-time market news.

ARAY

Accuray

$5.20

0.05 (0.97%)

, TSS

TSYS

$83.92

0.17 (0.20%)

17:27
01/23/18
01/23
17:27
01/23/18
17:27

On The Fly: After Hours Movers

UP AFTER EARNINGS: Accuray (ARAY), up 9.6%... TSYS (TSS), up 2.2%. ALSO HIGHER: Cerus Corporation (CERS), up 21.9% after it reported "positive" top-line results from its Phase 3 study in Thalassemia patients... Network-1 Technologies (NTIP), up 5.8% after it received a favorable ruling from a federal circuit court over a Covered Business Method Review challenged made by Google (GOOG) and YouTube... Qiagen (QGEN), up 1.8% after it received FDA clearance for its first-ever JAK2 test... SiriusXM (SIRI), up 1.2% after it approved an additional $2B to its stock repurchase program... Valero Energy (VLO), up 1% after it raised its dividend 14% and announced an additional $2.5B share repurchase authorization. DOWN AFTER EARNINGS: United Continental (UAL), down 5.4%... Navient (NAVI), down 3.3%... Cree (CREE), down 2.9%... Capital One (COF), down 1.8%... Texas Instruments (TXN), down 0.4%. ALSO LOWER: Puma Biotechnology (PBYI), down 28.6% after it said that the EMA communicated a negative trend vote over the company's MAA for neratinib... Sigma Designs (SIGM), down 10% after it said it will sell its Z-Wave business to Silicon Labs (SLAB) for $240M... Five Prime (FPRX), down 7.9% after it filed to sell $75M in common stock... Rocket Pharmaceuticals (RCKT), down 7.8% after it filed to sell common stock... Teekay Corp. (TK), down 7.7% after it filed to sell 10M shares of common stock... Strongbridge Biopharma (SBBP), down 4.6% after it filed to sell 5M shares of common stock.

ARAY

Accuray

$5.20

0.05 (0.97%)

TSS

TSYS

$83.92

0.17 (0.20%)

CERS

Cerus

$4.33

0.14 (3.34%)

NTIP

Network-1 Technologies

$2.60

0.1 (4.00%)

GOOG

Alphabet

$1,169.97

14.16 (1.23%)

GOOGL

Alphabet Class A

$1,176.17

12.01 (1.03%)

QGEN

Qiagen

$33.55

0.5 (1.51%)

SIRI

SiriusXM

$5.68

0.03 (0.53%)

VLO

Valero

$98.69

-0.26 (-0.26%)

UAL

United Continental

$77.97

1.1 (1.43%)

NAVI

Navient

$13.44

-0.08 (-0.59%)

CREE

Cree

$35.02

-1.67 (-4.55%)

COF

Capital One

$105.71

0.22 (0.21%)

TXN

Texas Instruments

$119.89

0.45 (0.38%)

PBYI

Puma Biotechnology

$90.90

-3.05 (-3.25%)

SIGM

Sigma Designs

$7.00

0.025 (0.36%)

FPRX

Five Prime

$22.43

0.14 (0.63%)

RCKT

Rocket Pharmaceuticals

$15.19

1.92 (14.47%)

TK

Teekay Corp.

$10.74

0.05 (0.47%)

SBBP

Strongbridge Biopharma

$8.70

0.25 (2.96%)

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 26

    Feb

  • 28

    Feb

  • 18

    Mar

  • 21

    Mar

  • 24

    Jan

  • 24

    Jan

  • 25

    Jan

  • 26

    Jan

ARAY Accuray
$5.20

0.05 (0.97%)

12/13/17
JPMS
12/13/17
DOWNGRADE
JPMS
Underweight
Accuray downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Tycho Peterson downgraded Accuray to Underweight saying he sees better risk/rewards else. The company has been unable to deliver consistent quarterly performances and this will likely continue, Peterson tells investors in a research note. The analyst does not have a price target on the shares.
11/30/17
11/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Spirit Airlines (SAVE) was initiated with an Overweight at Stephens, while JetBlue (JBLU) initiated with an Equal Weight. 2. Consol Energy (CEIX) was initiated with a Buy at Seaport Global and Stifel. 3. Evoqua Water (AQUA) initiated with a Neutral at JPMorgan. 4. Accuray (ARAY) initiated with a Buy at Lake Street. 5. Capstone (CCT) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/30/17
LSCM
11/30/17
INITIATION
Target $10
LSCM
Buy
Accuray initiated with a Buy at Lake Street
Lake Street analyst Brooks O'Neil started Accuray with a Buy rating and $10 price target. The analyst believes low expectations provide an "opportune time" for investors to look at the stock. Product improvements expand Accuray's addressable market and improve its competitive position, O'Neil contends.
12/13/17
12/13/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. TiVo (TIVO) downgraded to Neutral from Buy at B. Riley FBR with analyst Eric Wold citing heightened concerns around the company's dispute with Comcast (CMCSA). 2. Accuray (ARAY) downgraded to Underweight from Neutral at JPMorgan with analyst Tycho Peterson saying he sees better risk/rewards elsewhere. 3. Ralph Lauren (RL) downgraded to Underperform from Neutral at BofA/Merrill analyst Heather Balsky saying the margin story is "dimming" and brand demand is "still not bright." 4. bluebird bio (BLUE) downgraded to Hold from Buy at Maxim with analyst Jason McCarthy saying the 20% spike in the stock price after the latest ASH data presentation gives the company a $9B valuation. 5. Public Storage (PSA) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Richard Hill saying he expects ongoing top line deceleration from a combination of declining occupancy and moderating rate growth along with limited near-term benefit from the company's development pipeline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TSS TSYS
$83.92

0.17 (0.20%)

12/19/17
NOMU
12/19/17
NO CHANGE
Target $87
NOMU
Buy
Nomura sees Capital One renewal concerns for TSYS as overblown
Nomura Instinet analyst Dan Dolev thinks TSYS (TSS) investors should not be worried about potential pricing pressure from Capital One's (COF) contract renewal. Renewals and "modest" pricing pressures are "business as usual" for TSYS, Dolev tells investors in a research note. The analyst says that while Capital One may account for over 10% of TSYS' traditional accounts on file, his analysis shows that the company could potentially absorb up to mid-teens pricing discount. He views TSYS as among the best positioned merchant acquirers heading into 2018. The analyst raised his price target for the shares to $87 from $79 and keeps a Buy rating on the shares.
12/21/17
OPCO
12/21/17
NO CHANGE
OPCO
Black Knight, Fiserv among beneficiaries of tax reform, says Oppenheimer
Oppenheimer analyst Glenn Greene anticipates Black Knight (BKI), Fiserv (FISV), Jack Henry (JKHY), SEI Investments (SEIC) and TSYS (TSS) could see the largest relative benefits given high percentage of domestic earnings, with 20%-plus estimated earnings accretion. Alternatively, the analyst believes Cognizant (CTSH), First Data (FDC) and Infosys (INFY) could see more modest benefit, considering Cognizant/Infosys' lower proportion of domestic earnings and First Data's elevated level of debt/interest expense. PayPal (PYPL) is not expected to benefit from tax reform, and could actually see a modest increase in its effective tax rate, he adds.
12/11/17
12/11/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Kimberly-Clark (KMB) downgraded to Sell from Neutral at Citi with analyst Wendy Nicholson citing "stiff competition" Kimberly-Clark faces "in multiple categories in multiple markets." 2. TSYS (TSS) downgraded to Neutral from Buy at Goldman Sachs with analyst James Schneider citing valuation with the shares approaching his unchanged price target of $80. 3. Paccar (PCAR) downgraded to Neutral from Overweight at JPMorgan with analyst Ann Duignan saying the North American Class 8 truck market is likely to peak in 2018 and Paccar's stock is likely to continue to see multiple compression. 4. Flowserve (FLS) downgraded to Hold from Buy at Stifel with analyst Nathan Jones saying he sees no near-term catalysts given his expectation of orders being flat to down in the fourth quarter. 5. Brixmor (BRX) downgraded to Neutral from Buy at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/10/18
EVER
01/10/18
UPGRADE
EVER
Outperform
TSYS upgraded to Outperform from In Line at Evercore ISI
CERS Cerus
$4.33

0.14 (3.34%)

05/23/17
CANT
05/23/17
NO CHANGE
Target $7
CANT
Overweight
Cerus price target lowered to $7 from $9 at Cantor
Cantor Fitzgerald analyst Bryan Brokmeier lowered his price target for Cerus to $7 following the announced platelet additive Solution supply shortage. The analyst keeps an Overweight rating on the shares.
04/17/17
COWN
04/17/17
NO CHANGE
Target $7
COWN
Outperform
Cerus price target lowered to $7.00 from $9.50 at Cowen
Cowen analyst Joshua Jennings lowered his price target on Cerus to $7.00 from $9.50 but believes the company is well positioned to capitalize on its market development efforts supporting the U.S. platelet opportunity. Jennings believes the INTERCEPT pathogen inactivation system will eventually become the gold standard for blood transfusion safety worldwide for plasma, platelets, and red blood cells. Jennings maintained his Outperform rating on Cerus shares.
01/04/18
CANT
01/04/18
INITIATION
Target $5
CANT
Overweight
Cerus assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald assumed coverage of Cerus with an Overweight rating and $5 price target.
NTIP Network-1 Technologies
$2.60

0.1 (4.00%)

GOOG Alphabet
$1,169.97

14.16 (1.23%)

01/18/18
JPMS
01/18/18
NO CHANGE
JPMS
Overweight
TiVo in 'great position' after expanded Google deal, says JPMorgan
JPMorgan analyst Sterling Auty says TiVo's (TIVO) expanded agreement with Google (GOOG, GOOGL) to cover the new YouTube TV puts the company in a "great position" to capitalize if subscribers leave larger pay-TV operators for skinny bundles and cord-cutting options. The analyst is "especially excited about this agreement given millennial YouTube content consumption." He keeps an Overweight rating on TiVo shares.
01/12/18
RHCO
01/12/18
NO CHANGE
Target $1250
RHCO
Buy
Alphabet price target raised to $1,250 from $1,180 at SunTrust
SunTrust analyst Youssef Squali kept his Buy rating and raised his price target on Alphabet to $1,250 as part of his "Favorite Internet Stocks; Bullish Thesis Strengthened" research note. Squali says the company represents "one of the best plays" on macro economy trends amid a shift to digital advertising, rising consumption of video, and growing use of cloud computing. The analyst also notes several of Alphabet's longer-term initiatives such as self-driving cars with Waymo and smart home technology with Nest.
01/12/18
MSCO
01/12/18
NO CHANGE
MSCO
Morgan Stanley most bullish on Amazon in large-cap internet
Morgan Stanley analyst Brian Nowak issued his 2018 outlook for U.S. internet names, saying among the large caps he is bullish on Amazon (AMZN) as he sees growing high margin revenues leading to upward revisions of estimates for the company. He is also positive on Facebook (FB), contending that core Facebook ad unit pricing can rise over 20% in 2018 and Instagram can add about $16B in ad revenue. Nowak also keeps an Overweight rating on Alphabet (GOOG), as he expects innovation to drive beats on revenue and profits. He has a $1,250 price target on Amazon, $215 price target on Facebook and a $1,210 target on Alphabet.
01/11/18
PIPR
01/11/18
NO CHANGE
Target $1300
PIPR
Overweight
Alphabet price target raised to $1,300 from $1,150 at Piper Jaffray
Piper Jaffray analyst Sam Kemp raised his price target on Alphabet (GOOG) to $1,300, saying Google Cloud Platform is gaining mindshare from smaller competitors in the public cloud space amid "ongoing feature improvements, accompanying platform evangelism, and adoption by younger companies". The analyst contends that as a #3 player in the field behind Amazon's (AMZN) AWS and Microsoft's (MSFT) Azure, GCP can still create "meaningful shareholder value" within the accelerating cloud environment. Kemp keeps his Overweight rating on Alphabet.
GOOGL Alphabet Class A
$1,176.17

12.01 (1.03%)

QGEN Qiagen
$33.55

0.5 (1.51%)

01/08/18
PIPR
01/08/18
NO CHANGE
PIPR
Qiagen, DiaSorin partnership could be disruptive to TB market, says Piper Jaffray
Piper Jaffray analyst William Quirk notes that Qiagen (QGEN) announced a partnership with DiaSorin to develop an automated QuantiFERONTB test for the LIAISON analyzers, and argues that it could be disruptive to the existing physician office latent TB market. The analyst believes the agreement could put pressure on some of Oxford's (OXFD) business and potentially force the company to sign a similar deal with a different immunoassay provider. Quirk points out that Oxford also announced preliminary Q4 revenue below the Street, and while the company did not explain the weak results, he believes it was from U.S. immigration weakness and China order timing.
01/03/18
EVER
01/03/18
INITIATION
Target $35
EVER
Outperform
Qiagen initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ross Muken initiated Qiagen with an Outperform rating and $35 price target.
01/22/18
LEHM
01/22/18
NO CHANGE
Target $60
LEHM
Overweight
Quidel price target raised to $60 from $50 at Barclays
Barclays analyst Jack Meehan raised his price target for Quidel (QDEL) to $60 from $50 and for Qiagen (QGEN) to $40 from $39 ahead of the companies' Q4 results. The fundamental drivers for the Life Science Tools & Diagnostics group are "on a solid footing" into earnings, Meehan tells investors in a research note. The analyst favors both names with Overweight ratings.
SIRI SiriusXM
$5.68

0.03 (0.53%)

01/19/18
DBAB
01/19/18
UPGRADE
Target $54
DBAB
Buy
Liberty SiriusXM upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Bryan Kraft upgraded Liberty SiriusXM to Buy and raised his price target for the shares to $54 from $46. The stock offers a more favorable vehicle for owning SiriusXM (SIRI) right now given the 20% discount to net asset value, Kraft tells investors in a research note. He believes SiriusXM is one of the top beneficiaries of tax reform within his coverage.
01/02/18
01/02/18
DOWNGRADE

Market Perform
SiriusXM downgraded to Market Perform after CRB ruling at Barrington
As previously reported, Barrington analyst James Goss downgraded SiriusXM to Market Perform from Outperform, citing the added uncertainty created by the "surprisingly high" royalty obligations imposed on the company by the Copyright Royalty Board. While the company may be able to offset this somewhat, the royalties "pose an undeniable challenge" to near-term results, Goss tells investors.
01/19/18
DBAB
01/19/18
UPGRADE
Target $6.5
DBAB
Buy
SiriusXM upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Bryan Kraft upgraded SiriusXM (SIRI) to Buy and raised his price target for the shares to $6.50 from $5.25. The analyst believes the company is one of the top beneficiaries of tax reform within his coverage universe. He believes, however, that Liberty SiriusXM (LSXMA) is a more favorable vehicle for owning SiriusXM right now. The analyst upgraded that stock to Buy this morning as well.
01/19/18
BUCK
01/19/18
INITIATION
Target $6.5
BUCK
Buy
SiriusXM initiated with a Buy at Buckingham
Buckingham initiated SiriusXM with a Buy and $6.50 price target.
VLO Valero
$98.69

-0.26 (-0.26%)

11/02/17
EVER
11/02/17
UPGRADE
EVER
Outperform
Valero upgraded to Outperform from In Line at Evercore ISI
Evercore ISI analyst Doug Terreson upgraded Valero to Outperform with a $94 price target. Terreson expects profits in Refining, Chemicals and Midstream will strengthen during 2018-2019 and does not believe consensus estimates reflect his positive outlook.
11/16/17
STPT
11/16/17
DOWNGRADE
STPT
Hold
Valero downgraded to Hold from Buy at Standpoint Research
01/03/18
FBCO
01/03/18
INITIATION
Target $91
FBCO
Neutral
Valero initiated with a Neutral at Credit Suisse
Credit Suisse analyst Kristina Kazarian started Valero with a Neutral rating and $91 price target as she sees limited incremental upside from here.
10/24/17
MACQ
10/24/17
DOWNGRADE
Target $79
MACQ
Neutral
Valero downgraded to Neutral on valuation at Macquarie
As previously reported, Macquarie downgraded Valero to Neutral from Outperform and raised its price target to $79 from $73. Coverage was transferred to analyst Jay Tobin who said Valero's superior asset base, and leverage to improving long-term crack spreads is increasingly discounted in the current prices as near-term risk to light heavy spread compression and uncertain RIN costs.
UAL United Continental
$77.97

1.1 (1.43%)

01/11/18
01/11/18
DOWNGRADE

Hold
Hawaiian Holdings downgraded to Hold on competition concerns at Argus
As previously reported, Argus analyst John Staszak downgraded Hawaiian Holdings (HA) to Hold from Buy as he expect Hawaiian's yields to deteriorate as both United Continental (UAL) and Southwest (LUV) enter the West Coast-to-Hawaii market. Additionally, Hawaiian's costs have recently been rising at a 6%-7% pace, noted Staszak, who lowered his 2017 and 2018 EPS estimates for the company to below consensus.
01/10/18
UBSW
01/10/18
NO CHANGE
Target $80
UBSW
Buy
United Continental investor event could be a catalyst, says UBS
UBS analyst Darryl Genovesi views United Continental as the stock in his group with the highest potential upside over the next few year. He believes the company's investor event at the end of the month will showcase its opportunity for better RASM performance. He also sees the company's opportunity coming down to a higher domestic mix, improving operational reliability, and better network connectivity. Genovesi reiterated his Buy rating and $80 price target on United Continental shares.
01/10/18
SBSH
01/10/18
UPGRADE
Target $90
SBSH
Buy
United Continental upgraded to Buy from Neutral at Citi
Citi upgraded United Continental to Buy from Neutral, citing the stock's attractive valuation as well as the airline's broad international exposure and opportunity for improved investor sentiment. The firm also believes the company's upcoming earnings release could be a potential catalyst, with management likely to present updated, and probably more believable, financial objectives. Citi has a $90 price target on United shares.
01/10/18
STFL
01/10/18
NO CHANGE
STFL
Delta, American Airlines named as top 2018 airline picks at Stifel
Stifel analyst Joseph DeNardi noted that U.S. airlines face another year of elevated capacity growth in 2018, seeing domestic supply as likely to increase 5%-5.5%. Based on his view of a noticeable shift in ULCC capacity away from legacy hubs and into non-hub markets and "surprising" competitive capacity trends, he selects Delta (DAL) and American (AAL) as his top two picks in the space for 2018. However, DeNardi also highlighted United (UAL) as his top trading idea to start 2018, as he sees the stock being poised to benefit from improving investor sentiment.
NAVI Navient
$13.44

-0.08 (-0.59%)

01/12/18
JPMS
01/12/18
DOWNGRADE
Target $13.5
JPMS
Underweight
Navient downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Richard Shane downgraded Navient to Underweight while raising his price target for the shares to $13.50 from $13. The analyst cites valuation for the downgrade and notes the company is integrating an acquisition and investing in growth opportunities.
01/08/18
OPCO
01/08/18
INITIATION
OPCO
Perform
Navient initiated with a Perform at Oppenheimer
As reported earlier, Oppenheimer analyst Ben Chittenden initiated Navient (NAVI) with a Perform rating. Chittenden says the bulk of the company revenue still comes from its legacy loan book and private student loan portfolio, and both of those segments are under pressure. The analyst adds that 2019 could mark a key turning point, when Navient's non-compete agreement with Sallie Mae (SLM) expires, allowing it to originate private student loans again.
11/14/17
LEHM
11/14/17
INITIATION
Target $17
LEHM
Overweight
Navient reinstated with an Overweight at Barclays
Barclays analyst Mark DeVries reinstated Navient with an Overweight rating and $17 price target. The acquisition of Earnest is a long-term positive that is not reflected in the current valuation, the analyst contends.
01/08/18
OPCO
01/08/18
INITIATION
OPCO
Perform
Navient initiated with a Perform at Oppenheimer
CREE Cree
$35.02

-1.67 (-4.55%)

01/23/18
TIGR
01/23/18
DOWNGRADE
TIGR
Neutral
Cree downgraded to Neutral from Strong Buy at Tigress Financial
01/23/18
01/23/18
DOWNGRADE
Target $35

Neutral
Cree downgraded to Neutral at Roth Capital
As previously reported, Roth Capital analyst Craig Irwin downgraded Cree to Neutral from Buy, with a $35 price target, saying the company will generate a larger portion of FY18 gross margins from SiC wafer sales, where the entry of new wafer suppliers will introduce 2H18 pricing pressure. The analyst continues to see the addressable SiC device market as a multiple of that estimated by third party industry analysts.
01/23/18
TIGR
01/23/18
DOWNGRADE
TIGR
Neutral
Tigress downgrades Cree to Neutral following recent rally
Tigress Financial analyst Ivan Feinseth downgraded Cree to Neutral from Strong Buy saying the stock is fairly valued following the recent rally. Further, increasing competition in the LED market and rising spending needs will make it harder for Cree to generate a positive return on capital in the near future, Feinseth tells investors in a research note. The analyst believes the turnaround at Cree and the benefits from the Wolfspeed acquisition "will take some time."
01/23/18
ROTH
01/23/18
DOWNGRADE
ROTH
Neutral
Cree downgraded to Neutral from Buy at Roth Capital
COF Capital One
$105.71

0.22 (0.21%)

01/02/18
DBAB
01/02/18
INITIATION
Target $110
DBAB
Hold
Capital One initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Ashish Sabadra initiated Capital One with a Hold rating and a price target of $110. Sabadra says that 2018 will see earnings growth for the company thanks to an accretive Cabela's acquisition and sustained efficiency improvement, but also warns about Capital One's subprime exposure and potential near-term capital allocation constraints.
12/22/17
12/22/17
UPGRADE

On The Fly: Top analyst upgrades
Catch up on today's top analyst upgrades with this list compiled by The Fly: 1. Digital Realty (DLR) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jennifer Fritzsche saying the 8% pullback in the shares since December 1 brings an attractive entry point considering improving fundamentals in fiscal 2018 and beyond. 2. Capital One (COF) upgraded to Buy from Neutral at Compass Point. 3. Red Robin (RRGB) was upgraded to Buy from Hold at Jefferies while Texas Roadhouse (TXRH) and Dunkin' Brands (DNKN) were upgraded to Hold from Underperform. 4. RE/MAX Holdings (RMAX) upgraded to Neutral from Sell at Compass Point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/04/18
GSCO
01/04/18
DOWNGRADE
GSCO
Buy
SunTrust downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman Sachs analyst Ryan Nash removed SunTrust (STI) from his firm's Conviction List but he keeps a Buy rating on the shares. The analyst upped his price target for the stock to $74 from $65. SunTrust does not have as much leverage to tax reform, higher short-term interest rates and deregulation as some of its peers, Nash tells investors in a research note. The analyst's top picks for 2018 are Capital One (COF), Ally Financial (ALLY), Comerica (CMA), Regions Financial (RF), KeyCorp (KEY) and Citizens Financial (CFG).
01/09/18
WELS
01/09/18
NO CHANGE
Target $112
WELS
Outperform
Capital One price target raised to $112 from $102 at Wells Fargo
Wells Fargo analyst Donald Fandetti raised his price target for Capital One to $112 from $102 as he believes the U.S. consumer remains quite healthy and the tax cuts could provide a slight tailwind. The analyst reiterates an Outperform rating on the shares.
TXN Texas Instruments
$119.89

0.45 (0.38%)

01/22/18
RBCM
01/22/18
NO CHANGE
Target $127
RBCM
Outperform
Texas Instruments price target raised to $127 from $112 at RBC Capital
RBC Capital analyst Amit Daryanani raised his price target on Texas Instruments to $127 ahead of its earnings, citing a "favorable macro backdrop, healthy trends in the auto sector, positive commentary from peers, conservative prior guidance, and tax reform tailwinds". Based on the company's revenue strength and margins, Daryanani contends that the company is on track to sustain above $5.50 of free cash flow per share by 2020, keeping his Outperform rating on Texas Instruments.
01/22/18
JEFF
01/22/18
NO CHANGE
Target $150
JEFF
Buy
Texas Instruments added to Franchise Pick List at Jefferies
Jefferies analyst Mark Lipacis added Texas Instruments to his firm's Franchise Pick List after boosting his price target for the shares to $150. The analyst has a Buy rating on the name.
01/19/18
BMOC
01/19/18
NO CHANGE
Target $138
BMOC
Outperform
Texas Instruments price target raised to $138 from $105 at BMO Capital
BMO Capital analyst Ambrish Srivastava raised his price target on Texas Instruments to $138 as part of his Semiconductors earnings preview research note. Srivastava incorporates the new lower tax rate into his model, also raising his FY18 EPS target to $5.08 from $4.48. The analyst keeps his Outperform rating and reiterates his bullish thesis on the company's " long-term earnings power and free cash flow generating ability" from the positive implications of growing 300nm manufacturing footprint.
01/22/18
JEFF
01/22/18
NO CHANGE
Target $150
JEFF
Buy
Texas Instruments price target raised to $150 from $111 at Jefferies
Jefferies analyst Mark Lipacis raised his price target for Texas Instruments to $150 saying the company is "uniquely positioned to benefit from multiple secular and cyclical trends." Those include secular demand from "10's of billions of IoT device shipments," gross margin expansion from consolidation-driven pricing strength and tax reform. The analyst views his five-year earnings per share bull-case of $8.80 as attainable. He keeps a Buy rating on Texas Instruments.
PBYI Puma Biotechnology
$90.90

-3.05 (-3.25%)

12/18/17
LEER
12/18/17
NO CHANGE
LEER
Puma Biotechnology, Clovis top picks in biotech for 2018 at Leerink
Leerink analyst Michael Schmidt expects oncology to remain an attractive area within Biotech in 2018. Key product launches, a rich set of pivotal trial results, and pending regulatory decisions among stocks he covers make 2018 a catalyst-rich year, particularly in the first half of 2018, the analyst contends. Puma Biotechnology (PBYI) and Clovis (CLVS) are Schmidt's top-picks with Incyte (INCY) as a close third. Additionally, he sees ImmunoGen (IMGN) and Karyopharm (KPTI) as attractive emerging small-caps for 2018.
01/22/18
FBCO
01/22/18
NO CHANGE
Target $147
FBCO
Outperform
Puma Biotechnology price target raised to $147 from $142 at Credit Suisse
Credit Suisse analyst Alethia Young raised her price target for Puma Biotechnology to $147 from $142, citing valuation and tax rate. The analyst reiterates an Outperform rating on the shares.
01/17/18
SBSH
01/17/18
NO CHANGE
Target $164
SBSH
Buy
Puma Biotechnology selloff yesterday a buying opportunity, says Citi
Citi analyst Yigal Nochomovitz recommends using yesterday's selloff in shares of Puma Biotechnology as a buying opportunity. The analyst does not believe the 8% pullback is company-specific given the weakness yesterday in the sector. Nochomovitz says he found additional favorable regulatory precedent for a positive Committee for Medicinal Products for Human Use opinion for neratinib. He continues to expect a positive CHMP opinion in February and sees "another very good opportunity" to get into the name before a key expected positive catalyst. Nochomovitz has a Buy rating on Puma with a $164 price target.
01/03/18
SBSH
01/03/18
NO CHANGE
Target $164
SBSH
Buy
Puma Biotechnology sold off on FDA database comments, says Citi
Citi analyst Yigal Nochomovitz attributes the 5% pullback yesterday in shares of Puma Biotechnology to a competing research firm highlighting that the FDA's Adverse Event Reporting System shows 137 adverse events and four deaths among patients receiving Nerlynx. The FAERS has "substantial limitations which FDA has publically acknowledged," Nochomovitz tells investors in a research note titled "Alert: Word to the Wise on Using FDA's Adverse Event Reporting." The analyst believes the FAERS data by themselves are not an indicator of the safety profile of a drug. He keeps a Buy rating on Puma with a $164 price target.
SIGM Sigma Designs
$7.00

0.025 (0.36%)

12/08/17
12/08/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. D.R. Horton (DHI) downgraded to Market Perform from Outperform at Keefe Bruyette. 2. Ball Corp. (BLL) and Silgan Holdings (SLGN) were downgraded to Underweight from Sector Weight at KeyBanc. 3. Ciena (CIEN) downgraded to Neutral from Overweight at Piper Jaffray with analyst Troy Jensen saying he sees 2018 being a more challenging year for the company. 4. Sigma Designs (SIGM) was downgraded to Hold from Buy at Lake Street, Benchmark, and Craig-Hallum. 5. HollyFrontier (HFC) downgraded to Underperform from Neutral at BofA/Merrill with analyst Doug Leggate citing full valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/11/17
ROTH
12/11/17
NO CHANGE
Target $105
ROTH
Buy
Silicon Laboratories price target raised to $105 from $100 at Roth Capital
Roth Capital analyst Suji Desilva raised his price target for Silicon Laboratories (SLAB) to $105 from $100 as he is encouraged by the company's planned diversifying acquisition of Sigma Designs (SIGM). The analyst reiterates a Buy rating on Silicon Laboratories' shares.
12/08/17
LSCM
12/08/17
DOWNGRADE
Target $7.05
LSCM
Hold
Sigma Designs downgraded to Hold from Buy at Lake Street
Lake Street analyst Jaeson Schmidt downgraded Sigma Designs (SIGM) to Hold citing the takeover by Silicon Laboratories (SLAB). The analyst does not see regulatory hurdles and sees little risk to the deal getting done. He raised his price target for Sigma shares to $7.05 from $7.
12/08/17
BNCH
12/08/17
DOWNGRADE
BNCH
Hold
Sigma Designs downgraded to Hold from Buy at Benchmark
Benchmark analyst Gary Mobley downgraded Sigma Designs (SIGM) to Hold saying the 26% takeover premium from Silicon Laboratories (SLAB) is a good deal for shareholders.
FPRX Five Prime
$22.43

0.14 (0.63%)

11/08/17
LEER
11/08/17
NO CHANGE
LEER
Outperform
Leerink sees Five Prime recovering some of yesterday's losses
After hosting an investor call to obtain additional information on the efficacy and safety profile of cabiralizumab in pancreatic cancer, Leerink analyst Michael Schmidt expects shares Five Prime Therapeutics (FPRX) will recover some of the losses from yesterday. The efficacy observed in yesterday's data look "quite promising," while safety looks very similar to what has been seen in Opdivo monotherapy trials historically, Schmidt tells investors in a research note. He notes that Five Prime partner Bristol-Myers (BMY) remains highly engaged in the cabiralizumab program. The analyst maintains an Outperform rating on Five Prime shares. The stock in midday trading is up 15%, or $3.85, to $29.71.
11/13/17
NOMU
11/13/17
NO CHANGE
Target $94
NOMU
Buy
Five Prime recent selloff looks unfounded, says Nomura Instinet
Nomura Instinet analyst Christopher Marai believes the cabira+nivo data has been taken out of context and that the recent selloff in shares of Five Prime Therapeutics looks unfounded. The data highlight "remarkable durable responses in patients not expected to respond," Marai tells investors in a research note. He points out that the IDO inhibitor epacadostat routinely only results in 10% benefit in overall response rate. Marai keeps a Buy rating on Five Prime with a $94 price target.
11/07/17
SBSH
11/07/17
NO CHANGE
Target $65
SBSH
Buy
Citi says data puts safety of Five Prime's cabiralizumab in question
The key point of today's abstract was 43% G3-5 toxicity related to Five Prime Therapeutics' cabiralizumab, which puts the safety of the drug in question, Citi analyst Robyn Karnauskas tells investors in a research note. The analyst, who notes the data do show some durable activity, does not know at what dose the safety issues occurred. It remains unclear at this point if the activity being seen is due to checkpoint or cabiralizumab's contribution, Karnauskas writes. She models a 35% probability to the cabiralizumab program, which contributes $34 to her price target of $65. The analyst has a Buy rating on Five Prime. The stock is down 34% to $28.67.
11/07/17
JEFF
11/07/17
NO CHANGE
Target $52
JEFF
Buy
Five Prime data not as strong as expected, says Jefferies
Jefferies analyst Eun Yang says the 10% overall response rate with Five Prime Therapeutics' cabiralizumab plus Opdivo in second-line pancreatic cancer is lower than expected and the six-month disease control rate of 13%. The data are "not as strong as we like to see," but compares reasonably to chemo combo in second-line pancreatic cancer, Yang tells investors in a research note. The analyst has a Buy rating on Five Prime Therapeutics with a $52 price target. The stock in midday trading is down 34% to $28.69.
RCKT Rocket Pharmaceuticals
$15.19

1.92 (14.47%)

TK Teekay Corp.
$10.74

0.05 (0.47%)

12/18/17
JEFF
12/18/17
INITIATION
Target $8
JEFF
Hold
Teekay Corp. assumed with a Hold at Jefferies
Jefferies analyst Randy Giveans assumed coverage of Teekay Corp. with a Hold rating and $8 price target. The analyst assumed coverage of 23 energy maritime shipping names saying the industry is "primed for significant improvement." For the first time in 10 years, the analyst expects capacity shortages with demand growth to outpace supply growth in every shipping sector in 2018.
06/09/17
MSCO
06/09/17
DOWNGRADE
MSCO
Underweight
Teekay Corp. downgraded to Underweight from Equal Weight at Morgan Stanley
06/09/17
MSCO
06/09/17
DOWNGRADE
Target $3
MSCO
Underweight
Teekay Corp. downgraded to Underweight at Morgan Stanley
As previously reported, Morgan Stanley downgraded Teekay Corp. (TK) to Underweight from Equal Weight and lowered its price target to $3 from $8. Analyst Fotis Giannakoulis said the Teekay group continues to have liquidity erosion and due to continued weakness in the oil and offshore market, combined with a cyclical downturn in shipping of crude and sees risk from parent Teekay Offshore's (TOO) ability to meet its cash flow obligations.
09/14/17
WELS
09/14/17
UPGRADE
Target $4
WELS
Outperform
Teekay Offshore Partners upgraded to Outperform with $4 target at Wells Fargo
Wells Fargo analyst Michael Webber upgraded Teekay Offshore Partners (TOO) to Outperform from Market Perform saying he sees better relative value in the stock and Teekay LNG (TGP) relative to Teekay Corp. (TK) and Teekay Tankers (TNK) heading into the fall. The analyst raised his price target for Teekay Offshore Partners to $4 from $3.50.
SBBP Strongbridge Biopharma
$8.70

0.25 (2.96%)

08/11/17
08/11/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Strongbridge Biopharma (SBBP) initiated with an Outperform at Oppenheimer. 2. Discovery (DISCA) initiated with a Neutral at Piper Jaffray. 3. MannKind (MNKD) initiated with a Buy at Maxim. 4. Veritone (VERI) initiated with a Buy at Roth Capital. 5. Esperion (ESPR) initiated with a Neutral at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/10/17
OPCO
08/10/17
INITIATION
Target $12
OPCO
Outperform
Strongbridge Biopharma initiated with an Outperform at Oppenheimer
Oppenheimer analyst Hartaj Singh started Strongbridge Biopharma with an Outperform rating and $12 price target. The company's two assets, Keveyis and Recorlev, both have "proven clinical data and prior use in their respective therapeutic categories," the analyst contends. He's "bullish on the story."
12/05/17
CANT
12/05/17
INITIATION
Target $14
CANT
Overweight
Strongbridge Biopharma initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald started Strongbridge Biopharma with an Overweight rating and $14 price target.
12/06/17
CANT
12/06/17
INITIATION
Target $14
CANT
Overweight
Cantor calls Strongbridge 'significantly undervalued' in initiation report
Cantor Fitzgerald analyst Elemer Piros last night initiated coverage of Strongbridge Biopharma with an Overweight rating and $14 price target. The analyst believes the ongoing commercialization of ultra orphan drug Keveyis in primary periodic paralysis as well as late-stage development of Recorlev in Cushing's makes Strongbridge attractive. Success on either front could drive a "major inflection point for the shares," the analyst contends. Piros views the company as "significantly undervalued."

TODAY'S FREE FLY STORIES

ROKU

Roku

$50.54

0.76 (1.53%)

, NFLX

Netflix

$358.65

-2.68 (-0.74%)

09:50
07/23/18
07/23
09:50
07/23/18
09:50
Recommendations
Roku, Netflix analyst commentary  »

Roku price target raised…

ROKU

Roku

$50.54

0.76 (1.53%)

NFLX

Netflix

$358.65

-2.68 (-0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

KR

Kroger

$28.78

0.64 (2.27%)

09:50
07/23/18
07/23
09:50
07/23/18
09:50
Options
Sweep buyers of Kroger short-term calls as shares see relative strength »

Sweep buyers of Kroger…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIYY

Barclays ETN+ FI Enhanced Global High Yield ETN Series B

$98.56

(0.00%)

09:47
07/23/18
07/23
09:47
07/23/18
09:47
Hot Stocks
Barclays ETN+ FI Enhanced Global High Yield ETN Series B falls -5.6% »

Barclays ETN+ FI Enhanced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$42.60

-2.63 (-5.81%)

09:47
07/23/18
07/23
09:47
07/23/18
09:47
Hot Stocks
Halliburton falls -5.7% »

Halliburton is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

ITW

Illinois Tool Works

$136.81

-10.04 (-6.84%)

09:47
07/23/18
07/23
09:47
07/23/18
09:47
Hot Stocks
Illinois Tool Works falls -6.4% »

Illinois Tool Works is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

EMES

Emerge Energy

$6.99

(0.00%)

09:47
07/23/18
07/23
09:47
07/23/18
09:47
Hot Stocks
Emerge Energy rises 5.8% »

Emerge Energy is up 5.8%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

HCLP

Hi-Crush Partners

$12.90

2.05 (18.89%)

09:47
07/23/18
07/23
09:47
07/23/18
09:47
Hot Stocks
Hi-Crush Partners rises 19.8% »

Hi-Crush Partners is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

DDE

Dover Downs

$3.04

1 (49.02%)

09:47
07/23/18
07/23
09:47
07/23/18
09:47
Hot Stocks
Dover Downs rises 50.5% »

Dover Downs is up 50.5%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

BIDU

Baidu

$259.54

-0.46 (-0.18%)

09:45
07/23/18
07/23
09:45
07/23/18
09:45
Downgrade
Baidu rating change  »

Baidu downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 10

    Sep

MED

Medifast

$171.25

-0.21 (-0.12%)

09:45
07/23/18
07/23
09:45
07/23/18
09:45
Recommendations
Medifast analyst commentary  »

Medifast price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

09:45
07/23/18
07/23
09:45
07/23/18
09:45
General news
Existing Home Sales to be reported at 10:00 »

June Existing Home Sales…

AMZN

Amazon.com

$1,813.84

(0.00%)

09:43
07/23/18
07/23
09:43
07/23/18
09:43
Hot Stocks
Trump calls Washington Post an 'expensive lobbyist' for Amazon »

President Trump tweeted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 26

    Jul

  • 16

    Aug

ARWR

Arrowhead

$16.02

(0.00%)

09:41
07/23/18
07/23
09:41
07/23/18
09:41
Recommendations
Arrowhead analyst commentary  »

Arrowhead fair value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRNC

Tronc

$16.21

(0.00%)

09:41
07/23/18
07/23
09:41
07/23/18
09:41
Periodicals
Tronc seen making 'massive' layoffs at Daily News, NY Post reports »

The Daily News, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCLP

Hi-Crush Partners

$10.85

(0.00%)

, HAS

Hasbro

$94.02

(0.00%)

09:40
07/23/18
07/23
09:40
07/23/18
09:40
Options
Unusually active option classes on open July 23rd »

Unusual total active…

HCLP

Hi-Crush Partners

$10.85

(0.00%)

HAS

Hasbro

$94.02

(0.00%)

DLTR

Dollar Tree

$86.45

(0.00%)

HPE

HP Enterprise

$15.47

(0.00%)

IBB

iShares Nasdaq Biotechnology Index

$118.23

(0.00%)

HAL

Halliburton

$45.23

(0.00%)

RHT

Red Hat

$147.89

(0.00%)

XLF

Financial Select Sector

$27.57

(0.00%)

BMY

Bristol-Myers

$56.71

(0.00%)

TSLA

Tesla

$313.49

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 01

    Aug

  • 01

    Aug

  • 01

    Aug

  • 07

    Aug

  • 08

    Aug

CHFS

CHF Solutions

$1.50

0.01 (0.67%)

09:38
07/23/18
07/23
09:38
07/23/18
09:38
Hot Stocks
CHF Solutions shares rise in early trade after VA contract circulated »

Shares of CHF Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPLO

Diplomat Pharmacy

$22.35

-2.575 (-10.33%)

09:35
07/23/18
07/23
09:35
07/23/18
09:35
Recommendations
Diplomat Pharmacy analyst commentary  »

Diplomat Pharmacy recent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

09:35
07/23/18
07/23
09:35
07/23/18
09:35
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

09:35
07/23/18
07/23
09:35
07/23/18
09:35
General news
U.S. existing home sales preview: »

U.S. existing home sales…

UGP

Ultrapar

$11.42

0.375 (3.40%)

09:33
07/23/18
07/23
09:33
07/23/18
09:33
Downgrade
Ultrapar rating change  »

Ultrapar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZZ

Cosan

$8.32

0.105 (1.28%)

09:32
07/23/18
07/23
09:32
07/23/18
09:32
Downgrade
Cosan rating change  »

Cosan downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$45.23

0.26 (0.58%)

09:32
07/23/18
07/23
09:32
07/23/18
09:32
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton says expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LPNT

LifePoint

$47.85

-0.75 (-1.54%)

, CYH

Community Health

$2.72

-0.055 (-1.99%)

09:32
07/23/18
07/23
09:32
07/23/18
09:32
Recommendations
LifePoint, Community Health, Apollo Global, HCA Healthcare analyst commentary  »

Deal activity could pick…

LPNT

LifePoint

$47.85

-0.75 (-1.54%)

CYH

Community Health

$2.72

-0.055 (-1.99%)

APO

Apollo Global

$35.39

-0.22 (-0.62%)

HCA

HCA Healthcare

$108.01

0.31 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 27

    Jul

  • 27

    Jul

  • 02

    Aug

  • 22

    Aug

BIDU

Baidu

$260.00

-2.32 (-0.88%)

09:31
07/23/18
07/23
09:31
07/23/18
09:31
Downgrade
Baidu rating change  »

Baidu downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 10

    Sep

SLM

Sallie Mae

$11.71

-0.11 (-0.93%)

, CHGG

Chegg

$29.07

-0.07 (-0.24%)

09:31
07/23/18
07/23
09:31
07/23/18
09:31
Hot Stocks
Sallie Mae, Chegg introduce enhanced Study Starter benefit »

Sallie Mae (SLM) and…

SLM

Sallie Mae

$11.71

-0.11 (-0.93%)

CHGG

Chegg

$29.07

-0.07 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.